Acera Surgical provides Restrata, a fully synthetic electrospun fiber matrix that serves as a scaffold for soft‑tissue repair and wound closure. The sub‑micron fibers enable rapid cellular infiltration while resisting enzymatic degradation, maintaining strength for 7–10 days before controlled hydrolytic resorption. Available in pre‑meshed, expandable, and micronized formats, it can be sutured, stapled, or dispersed to suit a variety of surgical applications.
Funding
$5.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Surgeons often rely on biologic grafts or xenografts for soft‑tissue repair and wound closure, which can introduce variability, risk of disease transmission, and limited durability, especially in hostile wound environments.
Solution
Acera Surgical offers Restrata, a fully synthetic, electrospun fiber matrix that mimics the structure of native extracellular matrix. The sub‑cellular fibers (sub‑micron to micron diameter) provide a scaffold that supports rapid cellular infiltration and tissue regeneration without animal or human components. The polymer composition resists enzymatic degradation, maintaining mechanical strength through the inflammatory and proliferative phases before resorbing via hydrolysis. Available in pre‑meshed, expandable, and micronized formats, Restrata can be sutured, stapled, or dispersed to fit a wide range of surgical and traumatic wounds, delivering consistent performance across multiple specialties.
Target Audience
Primary customers are surgeons and interventional physicians in orthopedic trauma, general trauma, oncology, head‑and‑neck, plastic‑reconstructive, and foot‑ankle specialties who require reliable soft‑tissue repair or reinforcement solutions.
Features
- Sub‑cellular electrospun fibers 10× smaller than a cell, enabling high‑density cell infiltration and uniform tissue integration
- Fully synthetic polymer matrix free of animal or human tissue, eliminating disease‑transmission risk and storage constraints
- Enzymatic resistance with controlled hydrolytic resorption, preserving strength for 7–10 days post‑implantation
- Multiple form factors (pre‑meshed, expandable up to 2× coverage, micronized dispersible) for flat, contoured, or irregular wound sites
- Compatible with standard suturing or stapling techniques; can be used under primary skin closure for reinforcement
- Supported by Level I randomized controlled trial data for chronic diabetic foot ulcers and extensive pre‑clinical publications